ACM 007
Alternative Names: ACM-007Latest Information Update: 26 Sep 2023
At a glance
- Originator ACM Biolabs
- Class Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Retinal disorders
Most Recent Events
- 25 Sep 2023 ACM Biolabs plans the proof of concept study in Retinal disorders in the first quarter of 2023 (ACM Biolabs pipeline, September 2023)
- 25 Sep 2023 Preclinical development in Retinal disorders in Singapore (Ophthalmic) (ACM Biolabs pipeline, September 2023)
- 23 Feb 2023 ACM Biolabs files a worldwide patent protection for the technology related to polymer-lipid hybrid nanoparticles, which consist of a lipid and a block copolymer